Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs DS 1123 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 17 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jul 2018.
- 21 Apr 2017 Planned End Date changed from 30 Apr 2017 to 30 Sep 2018.